NKGen Biotech RGB small.jpg
NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer
January 10, 2023 13:27 ET | NKGen Biotech
SANTA ANA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell therapies,...
22157.jpg
Natural Killer Cells Therapeutics Global Market Report 2022: Rise in Awareness about Immunotherapies Bolsters Sector
December 09, 2022 05:33 ET | Research and Markets
Dublin, Dec. 09, 2022 (GLOBE NEWSWIRE) -- The "Natural Killer Cells Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Type (Natural Killer...
NKGen Biotech RGB small.jpg
NKGen Biotech Announces Publication in Journal of Cancer Research and Cellular Therapeutics on Durable Response for SNK01 in Advanced Sarcoma
September 21, 2022 13:09 ET | NKGen Biotech
SANTA ANA, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell...
Global Natural Killer Cells Therapeutics Market
Insights on the Natural Killer Cells Therapeutics Global Market to 2027 - by Therapeutics, Application, End-user and Region
July 01, 2022 07:13 ET | Research and Markets
Dublin, July 01, 2022 (GLOBE NEWSWIRE) -- The "Natural Killer Cells Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
22157.jpg
Global Immuno-Oncology Diagnostics Market Research Report 2022-2026: Diagnostics Plays New Key Role in Therapeutic Development and Clinical Trials
June 08, 2022 03:53 ET | Research and Markets
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics, Including Executive/Consultant Guides and Customized Forecasting/Analysis 2022 - 2026" report has...
Atyr_Logo.png
aTyr Pharma Announces New tRNA Synthetase Discovery Programs
February 11, 2021 08:00 ET | aTyr Pharma, Inc.
Advancement of selected AARS and DARS fragments primarily targeting cancer Programs will accelerate discoveries initially focusing on natural killer (NK) cell biology SAN DIEGO , Feb. 11, 2021 ...
22157.jpg
Global Immuno-Oncology Diagnostics Market 2019-2023 - Outcome Potential, Companion Diagnostics, Funding, Technology Environment, and Target Solutions Driving Growth
August 27, 2020 06:48 ET | Research and Markets
Dublin, Aug. 27, 2020 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Diagnostics: The Race for Biomarkers - Market Forecasts for Immuno-Oncology Diagnostics - With Executive and Consultant Guides and...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection
January 29, 2020 07:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO and WARREN, N.J., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initated a clinical and manufacturing collaboration with...